Low Back Pain: Do Guidelines Get it Right?

Obesity & Pain Management: A Primary Viewpoints Podcast

The opioid-sparing IVIB pain management strategy in adults aged 60 and older was effective in the immediate post-surgical period and associated with limited AEs.

FDA Submission Planned for Nonopioid Cebranopadol Following Positive Phase 3 Results: Tris Pharma Update

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.

FDA Approves Expanded Use for Sublocade for Opioid Use Disorder

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Patient Care Editorial Staff

Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose

These label changes to Sublocade from Indivior mark a significant advancement in the management of moderate to severe opioid use disorder.

IV Ibuprofen Cuts Postop Opioid Use by 23% in Older Adults, Study Finds

Your daily dose of the clinical news you may have missed.

Related Content

Obesity & Pain Management: A Primary Viewpoints Podcast

The opioid-sparing IVIB pain management strategy in adults aged 60 and older was effective in the immediate post-surgical period and associated with limited AEs.

FDA Submission Planned for Nonopioid Cebranopadol Following Positive Phase 3 Results: Tris Pharma Update

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.

FDA Approves Expanded Use for Sublocade for Opioid Use Disorder

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Patient Care Editorial Staff

Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose

These label changes to Sublocade from Indivior mark a significant advancement in the management of moderate to severe opioid use disorder.